ESC Professional Premium Access

SGLT2 inhibitors should be first-line treatment in HFrEF - discussion

Congress Presentation

5 more presentations in this session

SGLT2 inhibitors should be first-line treatment in HFrEF: pro

Speaker: Professor M. Packer (Dallas, US)

Thumbnail

SGLT2 inhibitors should be first-line treatment in HFrEF: con

Speaker: Professor J. Cleland (Glasgow, GB)

Thumbnail

There is a role for anticoagulation in patients with HFrEF in sinus rhythm: pro

Speaker: Associate Professor F. Marin (Murcia, ES)

Thumbnail

There is a role for anticoagulation in patients with HFrEF in sinus rhythm: con

Speaker: Doctor C. Reddin (Galway, IE)

Thumbnail

There is a role for anticoagulation in patients with HFrEF in sinus rhythm - discussion

Thumbnail

Access the full session

Great Debate: controversies in the contemporary management of HFrEF

Speakers: Professor M. Packer, Professor J. Cleland, Associate Professor F. Marin, Doctor C. Reddin
Thumbnail

About the event

Image

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

ESC 365 is supported by